News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,951 Results
Type
Article (14025)
Company Profile (304)
Press Release (248622)
Section
Business (79407)
Career Advice (152)
Deals (13208)
Drug Delivery (34)
Drug Development (50364)
Employer Resources (31)
FDA (5693)
Job Trends (5120)
News (144214)
Policy (10019)
Tag
Academia (901)
Alliances (21580)
Alzheimer's disease (779)
Antibody-drug conjugate (ADC) (67)
Approvals (5680)
Artificial intelligence (82)
Bankruptcy (99)
Best Places to Work (4542)
Biotechnology (249)
Breast cancer (121)
Cancer (1007)
Cardiovascular disease (83)
Career advice (132)
CAR-T (82)
Cell therapy (241)
Clinical research (40348)
Collaboration (380)
Compensation (152)
COVID-19 (1013)
C-suite (99)
Cystic fibrosis (72)
Data (1048)
Diabetes (95)
Diagnostics (1217)
Earnings (29054)
Events (47385)
Executive appointments (308)
FDA (6120)
Funding (362)
Gene editing (70)
Gene therapy (180)
GLP-1 (329)
Government (1066)
Healthcare (6559)
Infectious disease (1054)
Inflammatory bowel disease (100)
IPO (7219)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1377)
Lung cancer (147)
Lymphoma (63)
Manufacturing (91)
Medical device (2564)
Medtech (2565)
Mergers & acquisitions (6170)
Metabolic disorders (287)
Neuroscience (1062)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1205)
Obesity (156)
Opinion (93)
Parkinson's disease (82)
Patents (68)
People (25232)
Phase I (14236)
Phase II (18760)
Phase III (11871)
Pipeline (448)
Postmarket research (851)
Preclinical (5979)
Radiopharmaceuticals (207)
Rare diseases (223)
Real estate (1411)
Regulatory (8354)
Research institute (932)
Series A (71)
Southern California (1082)
Startups (1967)
United States (9551)
Vaccines (174)
Weight loss (92)
Date
Today (74)
Last 7 days (237)
Last 30 days (1166)
Last 365 days (20406)
2025 (1104)
2024 (20574)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11739)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (17019)
Australia (2873)
California (2746)
Canada (873)
China (250)
Colorado (103)
Connecticut (116)
Europe (36600)
Florida (308)
Georgia (79)
Illinois (170)
Indiana (67)
Maryland (366)
Massachusetts (2178)
Minnesota (111)
New Jersey (680)
New York (753)
North Carolina (445)
Northern California (1205)
Ohio (88)
Pennsylvania (525)
South America (207)
Southern California (1082)
Texas (309)
Washington State (266)
262,951 Results for "autifony therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
November 14, 2023
·
2 min read
·
Tyler Patchen
Biotech Bay
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
Autifony Therapeutics Limited announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.
November 14, 2023
·
2 min read
Autifony Therapeutics announces commencement of a US Phase Ib study of AUT00201, a novel Kv3 modulator, in Progressive Myoclonic Epilepsy-7 (EPM7)
Autifony Therapeutics Limited announced that a Phase Ib trial of AUT00201, a potent and selective modulator of Kv3 ion channels, is enrolling patients with Myoclonus Epilepsy and Ataxia due to Potassium Channel Mutation or MEAK at the Hospital of the University of Pennsylvania.
June 13, 2023
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 14, 2025
·
10 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics
January 10, 2025
·
3 min read
Press Releases
ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
January 13, 2025
·
5 min read
Layoff Tracker
Notch Therapeutics to ‘Significantly Reduce’ Workforce
2024 was a tough year for the biopharma industry, with several companies cutting hundreds or even thousands of employees. Follow along as
BioSpace
tracks job cuts and restructuring initiatives throughout 2025.
January 17, 2025
·
104 min read
·
BioSpace Editorial Staff
1 of 26,296
Next
